Fisher Asset Management LLC Sells 907 Shares of Becton, Dickinson and Company (NYSE:BDX)

Fisher Asset Management LLC lowered its position in Becton, Dickinson and Company (NYSE:BDX) by 45.6% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 1,083 shares of the medical instruments supplier’s stock after selling 907 shares during the period. Fisher Asset Management LLC’s holdings in Becton, Dickinson and Company were worth $261,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Livelsberger Financial Advisory bought a new position in shares of Becton, Dickinson and Company in the third quarter worth about $26,000. Ashton Thomas Securities LLC purchased a new position in Becton, Dickinson and Company in the 3rd quarter worth approximately $33,000. Tompkins Financial Corp lifted its holdings in Becton, Dickinson and Company by 44.2% in the 3rd quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock worth $36,000 after purchasing an additional 46 shares in the last quarter. Sound Income Strategies LLC boosted its stake in Becton, Dickinson and Company by 35.8% in the 3rd quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock worth $40,000 after purchasing an additional 44 shares during the period. Finally, Kennebec Savings Bank purchased a new stake in Becton, Dickinson and Company during the 3rd quarter valued at approximately $46,000. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. Evercore ISI upped their target price on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Citigroup raised shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and increased their price objective for the company from $255.00 to $275.00 in a report on Tuesday, October 1st. Finally, StockNews.com raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $283.00.

Becton, Dickinson and Company Trading Down 0.0 %

Shares of BDX opened at $221.90 on Monday. Becton, Dickinson and Company has a twelve month low of $218.75 and a twelve month high of $249.89. The company has a current ratio of 1.17, a quick ratio of 0.74 and a debt-to-equity ratio of 0.69. The company’s fifty day simple moving average is $234.16 and its 200-day simple moving average is $234.10. The company has a market cap of $64.14 billion, a P/E ratio of 37.36, a P/E/G ratio of 1.65 and a beta of 0.43.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.77 by $0.04. The business had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. Becton, Dickinson and Company had a net margin of 8.55% and a return on equity of 14.89%. The firm’s quarterly revenue was up 6.9% compared to the same quarter last year. During the same quarter last year, the firm earned $3.42 earnings per share. As a group, analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 31st. Shareholders of record on Monday, December 9th will be paid a $1.04 dividend. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. The ex-dividend date of this dividend is Monday, December 9th. This represents a $4.16 dividend on an annualized basis and a yield of 1.87%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 63.97%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.